AoPGBIAoPGBI
  • AoP
        • The AoP Home Area

        • Welcome from the President
        • President Professor Seamas Donnelly

          Prof. Seamas Donnelly
          Head of Department
          Trinity College Dublin

        • About Us
        • Our History
        • Our People
        • Governance and Structure
        • AoPGBI Secretariat

          Association Services Ltd, 33 St James’s Square London SW1Y 4JS
          0207 129 1261
          aopgbi@associationsltd.co.uk
          Contact Form
  • Fellows & Membership
        • Fellows and Membership

        • AoP Fellowship Scheme
        • Fellows Directory
        • Membership Categories, Pricing & Application Forms
        • Membership Information
  • Grants
        • The AoP Grants

        • Grants Schemes
        • Starter Grants for Clinical Lecturers
        • Summer Studentship
        • Young Investigator Awards
        • Links with Developing Countries
  • Engagement
        • Webinar Series:

        • Webinar Grand Round Series

        • Journal and Podcasts

        • AoP Forthcoming Webinar Series
        • AoP webinar channel

        • Webinar Ground Round Series
          Call for cases

        • QJM: An International Journal of Medicine
  • Annual Meeting
        • Annual Meeting

        • APAM Liverpool 2023
        • About our Meetings and Events
  1. Home
  2. Young Investigator Awards
  3. Young Investigator Awardees

Young Investigator Awardees

Professor Dear completed a PhD in Pharmacology at University College London before finishing his medical training at Oxford University. After junior medical jobs in Oxford and London, Professor Dear spent 2 years as a visiting research fellow at the National Institutes of Health, Bethesda, USA. Since 2005, Professor Dear has been at the University of Edinburgh. In 2012, he was awarded an NHS Research Scotland (NRS) Career Research Fellowship and in 2017 he was awarded the Grahame-Smith Prize for Excellence in Clinical Pharmacology. In 2020 Professor Dear was promoted to a personal chair in Clinical Pharmacology.

Professor James Dear

Project Summary

Acute liver failure (ALF) has no effective treatment other than liver transplantation, which has limited use because of its associated morbidity/mortality, expense and the scarcity of donor livers. In the Western world, paracetamol (acetaminophen) overdose (POD) is the commonest cause of ALF (around 100,000 POD/year in UK). There are at least 1000 POD-ALF cases treated in liver transplant centres in the US and EU (mostly UK) each year. Mortality in this group is around 30-35%, with about 30% receiving a liver transplant. The only treatment for POD is acetylcysteine (NAC), which is only fully effective if started soon after overdose (within 8h). There is no treatment for non-POD ALF. When the liver is injured, renal function is crucial in determining patient outcome. We proposed that the microRNA species, miR-122, released from the injured liver regulates renal function.

Findings

Kidney cells internalise microRNA with a subsequent change in gene expression. Circulating microRNAs increase substantially when released from an injured organ, such as following drug-induced liver injury (DILI). We explored whether functional liver-derived microRNA is transferred to the kidney. When liver microRNA was depleted in a mouse model there was a fall in miR-122 (hepatocyte-enriched) in the kidney.  Conversely, following DILI there was increased liver-derived miR-122 in kidney tubular cells. Liver-derived microRNA regulated kidney cytochrome P450 2E1 and inhibited toxic injury. This signalling pathway is potentially active in humans – urinary miR-122 was increased with DILI. These findings demonstrate that functional liver microRNA is transferred into kidney tubular cells to regulate gene expression, a signalling mechanism increased by drug toxicity. This microRNA already represents a drug target – miravirsen, a locked nucleic acid-modified DNA antisense oligonucleotide which specifically binds miR-122 – has demonstrated efficacy in a clinical trial to treat hepatitis C. Medicines which target miR-122 may also be effective treatments to prevent renal failure in patients with liver disease.

  • GRANTS
  • Starter Grants for Clinical Lecturers
  • Young Investigator Awards
  • Young Investigator Awardees
  • Links with Developing Countries
  • Summer Studentship
FOLLOW OUR SOCIAL MEDIA COMMUNITY
  • Contact Us
  • @AoPgbi
  • aopgbi
© The Association of Physicians 2021 | The Association of Physicians of Great Britain & Ireland is registered with the Charity Commission for England & Wales as charity number 207530.
  • Contact Us
  • @AoPgbi
  • aopgbi
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject Read More

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT